RITAZAREM Trial — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Rituximab maintenance was superior to Azathioprine in preventing relapse in patients with relapsing GPA/MPA
The best answer is “Rituximab maintenance was superior to Azathioprine in preventing relapse in patients with relapsing GPA/MPA”. Rituximab maintenance was superior to Azathioprine in preventing relapse in patients with relapsing GPA/MPA is supported by the cited UK or directly applicable specialist authority and best matches the tested threshold, complication or monitoring principle. The remaining choices—“Rituximab caused more infections, after specialist assessment, with clinical reassessment, within a rheumatology pathway”, “Both were equally ineffective, with clinical reassessment, within a rheumatology pathway, after safety review”, “No difference, after safety review, within a rheumatology pathway, after safety review, after specialist assessment”, “Azathioprine was superior, after specialist assessment, after safety review, after specialist assessment, with clinical reassessment”—are credible in related rheumatology presentations, but each addresses a different diagnosis, investigation, treatment sequence or complication and does not fit the decisive findings in this stem.
Reference: NICE NG100 rheumatoid arthritis in adults: https://www.nice.org.uk/guidance/ng100/chapter/Recommendations